Double Targeting of B Cells and Plasma Cells Using Low-Dose Obinutuzumab and Daratumumab in a Cohort of Severe Resistant Primary Focal Segmental Glomerulosclerosis, Idiopathic Membranous Nephropathy, and Lupus Nephritis
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Double Targeting of B Cells and Plasma Cells Using Low-Dose Obinutuzumab and Daratumumab in a Cohort of Severe Resistant Primary Focal Segmental Glomerulosclerosis, Idiopathic Membranous Nephropathy, and Lupus Nephritis. // Kidney Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S2590059526003419?dgcid=rss_sd_all
Double Targeting of B Cells and Plasma Cells Using Low-Dose Obinutuzumab and Daratumumab in a Cohort of Severe Resistant Primary Focal Segmental Glomerulosclerosis, Idiopathic Membranous Nephropathy, and Lupus Nephritis. Kidney Medicine. https://www.sciencedirect.com/science/article/pii/S2590059526003419?dgcid=rss_sd_all
“Double Targeting of B Cells and Plasma Cells Using Low-Dose Obinutuzumab and Daratumumab in a Cohort of Severe Resistant Primary Focal Segmental Glomerulosclerosis, Idiopathic Membranous Nephropathy, and Lupus Nephritis.” Kidney Medicine.
@article{article154911,
title = {Double Targeting of B Cells and Plasma Cells Using Low-Dose Obinutuzumab and Daratumumab in a Cohort of Severe Resistant Primary Focal Segmental Glomerulosclerosis, Idiopathic Membranous Nephropathy, and Lupus Nephritis},
journal = {Kidney Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S2590059526003419?dgcid=rss_sd_all}
}